Immuneering 的 IMM-1-104 是一种胰腺癌疗法，获得 FDA 孤儿药资格认定。 Immuneering's IMM-1-104, a pancreatic cancer therapy, receives FDA orphan drug designation.

Immuneering Corporation 已获得 FDA 的 IMM-1-104 孤儿药资格认定，IMM-1-104 是一种针对胰腺癌的研究性疗法。 Immuneering Corporation has received orphan drug designation from the FDA for IMM-1-104, an investigational therapy for pancreatic cancer. 这一指定可提供税收抵免和营销排他性等奖励措施。 This designation may provide incentives like tax credits and marketing exclusivity. 该药物处于第2阶段a试验阶段,显示初步效果良好,与化疗相结合的胰腺癌病人的总体反应率达到40%。 The drug is in a Phase 2a trial, showing promising initial results with a 40% overall response rate in pancreatic cancer patients when combined with chemotherapy. 该公司的股份在新闻报导后上升了20%以上。 The company's shares rose over 20% following this news.